Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitric oxide

A D Milner1

  • 1Department of Paediatrics, UMDS (St. Thomas' Hospital), London, UK.

European Journal of Pediatrics
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Inhaled nitric oxide (NO) shows promise for treating persistent pulmonary hypertension of the newborn (PPHN). This therapy effectively reduces pulmonary vasoconstriction and improves oxygenation in infants with PPHN.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How do the two visual streams interact with each other?

Experimental brain research·2017
Same author

The nature and limits of orientation and pattern processing supporting visuomotor control in a visual form agnosic.

Journal of cognitive neuroscience·2013
Same author

Is visual processing in the dorsal stream accessible to consciousness?

Proceedings. Biological sciences·2012
Same author

Streams and consciousness: visual awareness and the brain.

Trends in cognitive sciences·2011
Same author

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer.

British journal of cancer·2010
Same author

Separate channels for processing form, texture, and color: evidence from FMRI adaptation and visual object agnosia.

Cerebral cortex (New York, N.Y. : 1991)·2010
Same journal

Ultrasound-guided midline catheters in the neonatal intensive care unit: a single-center pilot study.

European journal of pediatrics·2026
Same journal

Gastrointestinal pathogens in paediatric patients with diarrhoea during the COVID-19 pandemic in Spain: a multicentre molecular-based prospective study.

European journal of pediatrics·2026
Same journal

Low serum immunoglobulin levels in pediatric atopic dermatitis: association with disease severity and exploratory scores.

European journal of pediatrics·2026
Same journal

Safely developing respiratory care during emergency neonatal transport through systematic collection and analysis of detailed ventilator data.

European journal of pediatrics·2026
Same journal

Validity and reliability of the Turkish version of the Physical Activity Parenting Questionnaire for Children.

European journal of pediatrics·2026
Same journal

Correction to: A novel oxygenation distension index (ODI): a driving pressure-based metric compared with the oxygenation index in pediatric PARDS.

European journal of pediatrics·2026
See all related articles

Area of Science:

  • Neonatal Medicine
  • Pulmonary Physiology
  • Pharmacology

Background:

  • Persistent pulmonary hypertension of the newborn (PPHN) involves pulmonary vasoconstriction, a common issue in severe respiratory distress.
  • Conventional treatments like high-pressure ventilation carry risks, and nonspecific vasodilators can cause systemic hypotension.

Purpose of the Study:

  • To explore inhaled nitric oxide (NO) as a targeted therapy for PPHN.
  • To evaluate the efficacy and safety of NO in reducing pulmonary vasoconstriction and improving oxygenation.

Main Methods:

  • Review of existing literature on NO synthesis and mechanism of action.
  • Analysis of animal studies demonstrating NO's effectiveness in relieving vasoconstriction.
  • Examination of preliminary clinical studies in adults and neonates with respiratory distress and PPHN.

Related Experiment Videos

Main Results:

  • Nitric oxide (NO) relaxes pulmonary smooth muscle by increasing cyclic guanosine monophosphate.
  • Animal studies confirm NO's safety and efficacy up to 100 ppm.
  • Preliminary human studies show reduced pulmonary artery pressure and improved oxygenation without systemic effects.

Conclusions:

  • Inhaled nitric oxide (NO) is a promising, targeted therapy for PPHN.
  • Further multicenter studies are needed to determine optimal concentrations and long-term safety.